| Literature DB >> 30649642 |
Hideki Nagano1,2, Toshimasa Izumi3, Ei Kawahara4, Takeru Oyama5, Takanori Goi6.
Abstract
BACKGROUND: Undifferentiated carcinoma of the esophagus with rhabdoid features is a very rare histologic finding that is occasionally associated with the loss of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1); however, until now, few survey reports of this type of tumor have been published. In this study, we describe a case of esophageal carcinoma with undifferentiated components and rhabdoid features that was exclusively positive for vimentin and SMARCB1 in a patient with prolonged survival. CASEEntities:
Keywords: CD34; Carcinoma with undifferentiated components; Esophagus; Rhabdoid features; Round cell carcinoma; SMARCB1; Vimentin
Year: 2019 PMID: 30649642 PMCID: PMC6335233 DOI: 10.1186/s40792-019-0562-4
Source DB: PubMed Journal: Surg Case Rep ISSN: 2198-7793
Fig. 1Endoscopic findings. An ulcerated tumor located in the lower esophagus (a) and extending to the upper stomach. The inferior border of the tumor was located in the gastric mucosa in a hiatal hernia (b)
Fig. 2Upper gastrointestinal (GI) fluoroscopy showed a transdiaphragmatic, circular ulcerative tumor that measured 7 cm along its major axis within the esophageal hiatus
Fig. 3Pathological findings of the resected primary tumor. A loupe image of the primary gastroesophageal region (a HE) shows that the tumor invades the muscular layer in the esophagus and the subserosal layer in the stomach. In the primary tumor, large uniform round-shaped cells with relatively little cytoplasm were arranged in a diffuse pattern (b HE, × 400), and some of the round cells showed prominent features of rhabdoid cells (c HE, × 400). The round tumor cells were prominently vimentin positive (e × 400) and weakly positive for cytokeratin (AE1/AE3) (d × 400). The cells were also positive for SMARCB1 (f × 400). The undifferentiated cells were positive for CD34 (g × 400), but negative for c-kit (h × 400)
Immunohistochemical antibodies used for tumor diagnosis
| IHC marker | Dilution | Company | Antibody |
|---|---|---|---|
| Pan-cytokeratin | Ready to use | Dako | AE1/AE3 |
| Low molecular cytokeratin | Ready to use | Becton Dickinson | CAM5.2 |
| High molecular cytokeratin | 1:50 | Dako | 34βE12 |
| CK 5/6 | Ready to use | Dako | D5/16 B4 |
| CK 7 | Ready to use | Dako | OV-TL 12/30 |
| CK 20 | Ready to use | Dako | Ks 20.8 |
| Vimentin | Ready to use | Dako | V9 |
| Myoglobin | Ready to use | Roche | Polyclonal |
| CD 30 | Ready to use | Dako | Ber-H2 |
| CD 34 | Ready to use | Dako | QBEnd 10 |
| LCA | Ready to use | Dako | PD7/26 and 2B11 |
| EMA | Ready to use | Dako | E29 |
| CA 19-9 | 1:50 | Dako | 1116-NS-19-9 |
| S 100 | Ready to use | Dako | Polyclonal |
| c-kit | 1:400 | Dako | Polyclonal |
| LMP-1 | 1:200 | Dako | CS.1-4 |
| Chromogranin A | Ready to use | Dako | Polyclonal |
| Synaptophysin | Ready to use | Nichirei | 27G12 |
| CD56 | Ready to use | Nichirei | MRQ-42 |
| SMARCB1 | 1:200 | Abnova | BAF47 |
Fig. 4Pathological findings of squamous differentiation in the lymph node (a HE, × 400). The carcinoma cells were positive for AE1/AE3 antibodies (b × 400) and focally positive for vimentin (c × 400). The carcinoma cells were exclusively positive for SMARCB1 (d; × 400). The squamous carcinoma differentiation was positive for cytokeratin 5/6 (e; × 400) and anti-high molecular cytokeratin antibodies, clone 34βE12 (f × 400). The SCC component was positive for chromogranin A (g × 400)
Results for immunohistochemistry
| Primary Round cell | Lymph Node Metastasis | ||
|---|---|---|---|
| Round cell | Epithelial | ||
| AE1/AE3 | − | + (focal) | ++ |
| CAM5.2 | − | − | ++ |
| 34βE12 | − | − | +(focal) |
| CK5/6 | − | − | +(focal) |
| CK7 | − | − | − |
| CK20 | − | − | − |
| Vimentin | ++ | ++ | + (focal) |
| Myoglobin | − | − | − |
| CD30 | − | − | − |
| CD34 | ++ | ++ | ++ |
| LCA | − | − | − |
| EMA | − | − | ++ |
| CA19-9 | − | − | − |
| S100 | − | − | − |
| c-kit | − | − | − |
| LMP-1 | − | − | − |
| Chromogranin A | − | − | +(focal) |
| Synaptophysin | − | − | +(focal) |
| CD56 | − | − | + |
| SMARCB1 | ++ | ++ | ++ |
| MIB1 index | 19.7% | 70.1% | 0.5% |
EMA epithelial membrane antigen, LCA leukocyte common antigen